Q3 EPS Estimate for Arcus Biosciences Boosted by Analyst

Arcus Biosciences, Inc. (NYSE:RCUS) – Stock analysts at HC Wainwright boosted their Q3 2026 earnings estimates for Arcus Biosciences in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($1.00) per share for the quarter, up from their prior estimate of ($1.07). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.60) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q4 2026 earnings at ($0.96) EPS, FY2026 earnings at ($4.35) EPS, FY2027 earnings at ($3.23) EPS, FY2028 earnings at ($2.18) EPS, FY2029 earnings at ($1.45) EPS and FY2030 earnings at ($0.61) EPS.

A number of other research analysts have also commented on the stock. Truist Financial assumed coverage on shares of Arcus Biosciences in a research report on Monday, May 18th. They set a “buy” rating and a $35.00 price target for the company. Wall Street Zen downgraded Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Wedbush lifted their price objective on Arcus Biosciences from $41.00 to $43.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Lifesci Capital started coverage on Arcus Biosciences in a research report on Thursday, June 4th. They set an “outperform” rating and a $46.00 target price for the company. Finally, Morgan Stanley set a $23.00 target price on Arcus Biosciences in a research note on Monday. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.80.

Arcus Biosciences Stock Performance

NYSE RCUS opened at $28.80 on Monday. Arcus Biosciences has a 1 year low of $9.22 and a 1 year high of $31.74. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82. The stock has a market capitalization of $3.67 billion, a PE ratio of -7.38 and a beta of 0.80. The company’s 50 day simple moving average is $27.54 and its two-hundred day simple moving average is $24.36.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.17. The company had revenue of $41.00 million during the quarter, compared to analysts’ expectations of $21.98 million. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The business’s quarterly revenue was down 74.4% on a year-over-year basis.

Insider Buying and Selling

In other news, CAO Alexander Azoy sold 2,562 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $25.77, for a total value of $66,022.74. Following the transaction, the chief accounting officer owned 39,581 shares of the company’s stock, valued at $1,020,002.37. This represents a 6.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Juan C. Jaen sold 48,502 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $30.05, for a total transaction of $1,457,485.10. Following the sale, the president owned 842,307 shares in the company, valued at approximately $25,311,325.35. This trade represents a 5.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 102,562 shares of company stock valued at $2,975,354. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Arcus Biosciences

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Arcus Biosciences in the 2nd quarter worth approximately $506,113,000. Wellington Management Group LLP grew its position in Arcus Biosciences by 309.4% during the fourth quarter. Wellington Management Group LLP now owns 5,184,509 shares of the company’s stock valued at $123,547,000 after acquiring an additional 3,918,220 shares during the last quarter. Marshall Wace LLP bought a new position in Arcus Biosciences during the fourth quarter valued at approximately $80,731,000. Suvretta Capital Management LLC raised its stake in shares of Arcus Biosciences by 40.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,188,858 shares of the company’s stock worth $123,650,000 after acquiring an additional 1,500,000 shares in the last quarter. Finally, Toronto Dominion Bank purchased a new position in shares of Arcus Biosciences during the fourth quarter worth approximately $35,380,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.